Raptiva (efalizumab)

DRUG5 trials

Sponsors

Genentech, Inc.

Conditions

Plaque PsoriasisPsoriasis

Phase 1

A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis

CompletedNCT00382512

Genentech, Inc.Plaque Psoriasis

Start: 2003-05-31Target: 60Updated: 2006-09-29

Phase 3

A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

CompletedNCT00096603

Genentech, Inc.Psoriasis

Start: 2002-10-31End: 2004-07-31Target: 450Updated: 2014-03-20

A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g

CompletedNCT00109252

Genentech, Inc.Psoriasis

Start: 2002-01-31End: 2003-04-30Updated: 2013-06-21

A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

CompletedNCT00109317

Genentech, Inc.Psoriasis

Start: 2002-09-30End: 2003-02-28Updated: 2013-06-21

Phase 4

A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

CompletedNCT00096980

Genentech, Inc.Psoriasis

Start: 2001-02-28End: 2004-05-31Target: 300Updated: 2013-06-21